Pathophysiology, clinical presentation, and treatment of psoriasis: a review
AW Armstrong, C Read - Jama, 2020 - jamanetwork.com
Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
Psoriasis pathogenesis and treatment
A Rendon, K Schäkel - International journal of molecular sciences, 2019 - mdpi.com
Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …
Psoriasis
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …
presenting at any age, and leading to a substantial burden for individuals and society. It is …
2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
A Menter, BE Strober, DH Kaplan, D Kivelevitch… - Journal of the American …, 2019 - Elsevier
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …
population. This guideline addresses important clinical questions that arise in psoriasis …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
Diagnosis and management of psoriasis
WB Kim, D Jerome, J Yeung - Canadian Family Physician, 2017 - cfp.ca
Objective To provide primary care clinicians with an up-to-date and practical overview of the
diagnosis and management of psoriasis. Quality of evidence PubMed, MEDLINE, EMBASE …
diagnosis and management of psoriasis. Quality of evidence PubMed, MEDLINE, EMBASE …
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled …
Background Psoriasis is an autoimmune disease that affects approximately 100 million
people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We …
people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We …
Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis
Abstract Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine
signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 …
signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 …
Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents
SB Kaushik, MG Lebwohl - Journal of the American Academy of …, 2019 - Elsevier
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …